Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 7/20 | 0.37 |
| ▸ | P2RX2 | Q9UBL9 | 7/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12393901 | 0.83 | MAPKAPK2 (0.41) | MAPKAPK2CDK5CDK5R1PIK3CB | |
| SCHEMBL12457045 | 0.80 | DHFR (0.36) | MAPKAPK2P2RX3P2RX2DHFR | |
| SCHEMBL24756693 | 0.77 | MAPKAPK2 (0.47) | MAPKAPK2CDK5CDK5R1PIK3CB | |
| SCHEMBL22907450 | 0.72 | DYRK1A (0.33) | — | |
| SCHEMBL10212533 | 0.70 | — | — | |
| SCHEMBL12732223 | 0.68 | KCNH2 (0.32) | — | |
| SCHEMBL30625076 | 0.68 | P2RX3 (0.54) | P2RX3P2RX2DHFR | |
| SCHEMBL1319169 | 0.68 | P2RX3 (0.54) | P2RX3P2RX2DHFR | |
| SCHEMBL12316236 | 0.66 | P2RX3 (0.47) | P2RX3P2RX2DHFR | |
| SCHEMBL2611029 | 0.66 | P2RX3 (0.45) | P2RX3P2RX2DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | MAPKAPK2 1905/4885CDK5 1473/4885CDK5R1 1381/4885 |
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | MAPKAPK2 1905/4885CDK5 1473/4885CDK5R1 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.